Reaction
Infusion Site Inflammation reporting signals
As of the last recalculation, Infusion Site Inflammation appears in 666 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is KETOPROFEN (PRR 117.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ketoprofen | 46 | 117.6 | 118.0 |
| Treprostinil | 277 | 117.4 | 117.7 |
| Amitriptyline Hydrochloride | 41 | 77.8 | 77.9 |
| 0Xygen | 61 | 42.5 | 42.6 |
| Oxygen | 61 | 42.5 | 42.6 |
| Sildenafil Powder, | 43 | 40.3 | 40.3 |
| Riociguat | 39 | 39.6 | 39.7 |
| Macitentan | 75 | 38.0 | 38.1 |
| Lidocaine Hydrochloride | 64 | 36.6 | 36.6 |
| Sildenafil | 61 | 36.1 | 36.2 |
| Clonidine | 46 | 30.1 | 30.1 |
| Tadalafil | 84 | 29.9 | 29.9 |
| Sodium Chloride Tablet | 61 | 28.4 | 28.4 |
| Sodium Chloride Tablets | 61 | 28.4 | 28.4 |
| Sodium Chloride | 61 | 26.5 | 26.5 |
| Selexipag | 21 | 26.2 | 26.2 |
| Ambrisentan | 82 | 23.3 | 23.3 |
| Sildenafil Citrate | 83 | 23.1 | 23.1 |
| Rasagiline Mesylate | 5 | 14.1 | 14.1 |